[Federal Register Volume 64, Number 212 (Wednesday, November 3, 1999)]
[Notices]
[Pages 59776-59779]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-28793]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 99N-4614]
Agency Emergency Processing Request Under OMB Review; Guidance
for Industry; Changes to an Approved NDA or ANDA
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information has been submitted to the Office of
Management and Budget (OMB) for emergency processing under the
Paperwork Reduction Act of 1995 (the PRA). The collection of
information is contained in a guidance for industry entitled ``Changes
to an Approved NDA or ANDA.'' The guidance is intended to assist
applicants in determining how they should report changes to an approved
new drug application (NDA) or abbreviated new drug application (ANDA)
under section 116 of the Food and Drug Administration Modernization Act
(the Modernization Act), which provides requirements for making and
reporting manufacturing changes to an approved application and for
distributing a drug product made with such changes.
DATES: Submit written comments on the collection of information by
November 10, 1999.
ADDRESSES: Submit written comments on the collection of information to
the Office of Information and Regulatory Affairs, OMB, New Executive
Office Bldg., 725 17th St. NW., rm 10235, Washington, DC 20503, Attn:
Desk Officer for FDA. All comments should be identified with the docket
number found in brackets in the heading of this document.
FOR FURTHER INFORMATION CONTACT: Karen L. Nelson, Office of Information
Resources Management (HFA-250), Food and Drug Administration, 5600
Fishers Lane, Rockville, MD 20857, 301-827-1482.
SUPPLEMENTARY INFORMATION: On November 21, 1997, the President signed
the Modernization Act (Public Law 105-115) into law. Section 116 of the
Modernization Act amended the Federal Food, Drug, and Cosmetic Act (the
act) by adding section 506A (21 U.S.C. 356a), which describes
requirements and procedures for making and reporting manufacturing
changes to approved NDA's and ANDA's, to new and abbreviated animal
drug applications, and to license applications for biological products.
The guidance for industry entitled ``Changes to an Approved NDA or
ANDA'' provides recommendations to holders of NDA's and ANDA's who
intend to make postapproval changes in accordance with section 506A of
the act. The guidance covers recommended reporting categories for
postapproval changes for drugs, other than specified biotechnology and
specified synthetic biological products. Recommendations are provided
for postapproval changes in: (1) Components and composition, (2) sites,
(3) manufacturing process, (4) specification(s), (5) package, (6)
labeling, and (7) miscellaneous changes.
With respect to the collection of information described below, FDA
invites comment on: (1) Whether the proposed collection of information
is necessary for the proper performance of FDA's functions, including
whether the information will have practical utility; (2) the accuracy
of FDA's estimate of the burden of the proposed collection of
information, including the validity of the methodology and assumptions
used; (3) ways to enhance the quality, utility, and clarity of the
information to be collected; and (4) ways to minimize the burden of the
collection of information on respondents, including through the use of
automated collection techniques,
[[Page 59777]]
when appropriate, and other forms of information technology.
Title: Changes to an Approved NDA or ANDA
Section 116 of the Modernization Act amended the act by adding
section 506A, which includes the following provisions:
1. A drug made with a manufacturing change, whether a major
manufacturing change or otherwise, may be distributed only after the
applicant validates the effects of the change on the identity,
strength, quality, purity, and potency of the drug as these factors may
relate to the safety or effectiveness of the drug (sections 506A(a)(1)
and (b) of the act). This section recognizes that additional testing,
beyond testing to ensure that an approved specification is met, is
required to ensure unchanged identity, strength, quality, purity, or
potency as these factors may relate to the safety or effectiveness of
the drug.
A drug made with a major manufacturing change may be distributed
only after the applicant submits a supplemental application to FDA and
the supplemental application is approved by the agency. The application
is required to contain information determined to be appropriate by FDA
and include the information developed by the applicant when
``validating the effects of the change'' (section 506A(c)(1) of the
act).
3. A major manufacturing change is a manufacturing change
determined by FDA to have substantial potential to adversely affect the
identity, strength, quality, purity, or potency of the drug as these
factors may relate to the safety or effectiveness of the drug. Such
changes include: (1) A change made in the qualitative or quantitative
formulation of the drug involved or in the specifications in the
approved application or license unless exempted by FDA by regulation or
guidance; (2) a change determined by FDA by regulation or guidance to
require completion of an appropriate clinical study demonstrating
equivalence of the drug to the drug manufactured without the change;
and (3) other changes determined by FDA by regulation or guidance to
have a substantial potential to adversely affect the safety or
effectiveness of the drug (section 506A(c)(2) of the act).
4. FDA may require submission of a supplemental application for
drugs made with manufacturing changes that are not major (section
506A(d)(1)(B) of the act) and establish categories of manufacturing
changes for which a supplemental application is required (section
506A(d)(1)(C) of the act). In such a case the applicant may begin
distribution of the drug 30 days after FDA receives a supplemental
application unless the agency notifies the applicant within the 30-day
period that prior approval of the application is required (section
506A(d)(3)(B)(i) of the act). FDA may also designate a category of
manufacturing changes that permit the applicant to begin distributing a
drug made with such changes upon receipt by the agency of a
supplemental application for the change (section 506A(d)(3)(B)(ii) of
the act). If FDA disapproves a supplemental application, the agency may
order the manufacturer to cease the distribution of drugs that have
been made with the disapproved change (section 506A(d)(3)(B)(iii) of
the act).
5. FDA may authorize applicants to distribute drugs without
submitting a supplemental application (section 506A(d)(1)(A) of the
act) and may establish categories of manufacturing changes that may be
made without submitting a supplemental application (section
506A(d)(1)(C) of the act). The applicant is required to submit a report
to FDA on such a change, and the report is required to contain
information the agency deems to be appropriate and information
developed by the applicant when validating the effects of the change.
FDA may also specify the date on which the report is to be submitted
(section 506A(d)(2)(A) of the act). If during a single year an
applicant makes more than one manufacturing change subject to an annual
reporting requirement, FDA may authorize the applicant to submit a
single report containing the required information for all the changes
made during the year (annual report) (section 506A(d)(2)(B) of the
act).
Section 506A of the act provides FDA with considerable flexibility
to determine the information and filing mechanism required for the
agency to assess the effect of manufacturing changes in the safety and
effectiveness of the product. There is a corresponding need to retain
such flexibility in the guidance on section 506A of the act to ensure
that the least burdensome means for reporting changes are available.
FDA believes that such flexibility will allow it to be responsive to
increasing knowledge of and experience with certain types of changes
and help ensure the efficacy and safety of the products involved. For
example, a change that may currently be considered to have a
substantial potential to have an adverse effect on the safety or
effectiveness of the product may, at a later date, based on new
information or advances in technology, be determined to have a lesser
potential to have such an adverse effect. Conversely, a change
originally considered to have a minimal or moderate potential to have
an adverse effect on the safety or effectiveness of the product may
later, as a result of new information, be found to have an increased,
substantial potential to adversely affect the product. The guidance
enables the agency to respond more readily to knowledge gained from
manufacturing experience, further research and data collection, and
advances in technology. The guidance describes the agency's current
interpretation of specific changes falling into the four filing
categories. Section 506A of the act explicitly provides FDA the
authority to use guidance documents to determine the type of changes
that do or do not have a substantial potential to adversely affect the
safety or effectiveness of the drug product. The use of guidance
documents allows FDA to more easily and quickly modify and update
important information.
Description of Respondents: Businesses or other for-profit
organizations.
As explained below, FDA estimates the burden of this collection of
information as follows:
Table 1.--Estimated Annual Reporting Burden \1\
----------------------------------------------------------------------------------------------------------------
Number of
Federal Food, Drug, and Cosmetic No. of Responses per Total Annual Hours per Total Hours
Act Sections Respondents Respondent Responses Response
----------------------------------------------------------------------------------------------------------------
506A(c)(1)
506A(c)(2)
Prior approval supplement
(supp.)
594 3 1,744 120 209,280
506A(d)(1)(B)
506A(d)(1)(C)
[[Page 59778]]
506A(d)(3)(B)(i)
Changes being effected (CBE) in
30-day supp.
594 5 2,754 80 220,320
506A(d)(1)(B)
506A(d)(1)(C)
506A(d)(3)(B)(ii)
CBE supp.
486 1 486 80 38,880
506A(d)(1)(A)
506A(d)(1)(C)
506A(d)(2)(A)
506A(d)(2)(B)
Annual Report 704 10 6,929 25 173,225
Total 641,705
----------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of
information.
Sections 506A(a)(1) and 506A(b) of the act require the holder of an
approved application to validate the effects of a manufacturing change
on the identity, strength, quality, purity, or potency of the drug as
these factors may relate to the safety or effectiveness of the drug
before distributing a drug made with the change. Under section
506A(d)(3)(A), information developed by the applicant to validate the
effects of the change regarding identity, strength, quality, purity,
and potency is required to be submitted to FDA as part of the
supplement or annual report. Thus, no separate estimates are provided
for these sections in the Table 1; estimates for validation
requirements are included in the estimates for supplements and annual
reports. The guidance does not provide recommendations on the specific
information that should be developed by the applicant to validate the
effect of the change on the identity, strength (e.g., assay, content
uniformity), quality (e.g., physical, chemical, and biological
properties), purity (e.g., impurities and degradation products), or
potency (e.g., biological activity, bioavailability, bioequivalence) of
a product as they may relate to the safety or effectiveness of the
product.
Sections 506A(c)(1) and 506A(c)(2) of the act set forth
requirements for changes requiring supplement submission and approval
prior to distribution of the product made using the change (major
changes). Under these sections, a supplement must be submitted for any
change in the product, production process, quality controls, equipment,
or facilities that has a substantial potential to have an adverse
effect on the identity, strength, quality, purity, or potency of the
product as these factors may relate to the safety or effectiveness of
the product. The applicant must obtain approval of a supplement from
FDA prior to distribution of a product made using the change.
Based on data concerning the number of supplements received by the
agency, FDA estimates that approximately 1,744 supplements will be
submitted annually under sections 506A(c)(1) and 506A(c)(2) of the act.
FDA estimates that approximately 594 applicants will submit such
supplements, and that it will take approximately 120 hours to prepare
and submit to FDA each supplement.
Under section 506A(d)(1)(B), 506A(d)(1)(C), and 506A(d)(3)(B)(i) of
the act set forth requirements for changes requiring supplement
submission at least 30 days prior to distribution of the product made
using the change (moderate changes). Under these sections, a supplement
must be submitted for any change in the product, production process,
quality controls, equipment, or facilities that has a moderate
potential to have an adverse effect on the identity, strength, quality,
purity, or potency of the product as these factors may relate to the
safety or effectiveness of the product. Distribution of the product
made using the change may begin not less than 30 days after receipt of
the supplement by FDA.
Based on data concerning the number of supplements received by the
agency, FDA estimates that approximately 2,754 supplements will be
submitted annually under sections 506A(d)(1)(B), 506A(d)(1)(C), and
506A(d)(3)(B)(i) of the act. FDA estimates that approximately 594
applicants will submit such supplements, and that it will take
approximately 80 hours to prepare and submit to FDA each supplement.
Under section 506A(d)(3)(B)(ii) of the act, FDA may designate a
category of changes for the purpose of providing that, in the case of a
change in such category, the holder of an approved application may
commence distribution of the drug upon receipt by the agency of a
supplement for the change. Based on data concerning the number of
supplements received by the agency, FDA estimates that approximately
486 supplements will be submitted annually under section
506A(d)(3)(B)(ii) of the act. FDA estimates that approximately 486
applicants will submit such supplements, and that it will take
approximately 80 hours to prepare and submit to FDA each supplement.
Sections 506A(d)(1)(A), 506A(d)(1)(C), 506A(d)(2)(A), and
506A(d)(2)(B) of the act set forth requirements for changes to be
described in an annual report (minor changes). Under these sections,
changes in the product, production process, quality controls,
equipment, or facilities that have a minimal potential to have an
adverse effect on the identity, strength, quality, purity, or potency
of the product as these factors may relate to the safety or
effectiveness of the product must be documented by the applicant in the
next annual report.
Based on data concerning the number of supplements and annual
reports received by the agency, FDA estimates that approximately 6,929
annual reports will include documentation of certain manufacturing
changes as required under sections 506A(d)(1)(A), 506A(d)(1)(C),
506A(d)(2)(A), and 506A(d)(2)(B) of the act. FDA estimates that
approximately 704 applicants will submit such information, and that it
will take approximately 25 hours to prepare and submit to FDA the
information for each annual report.
In the Federal Register of June 28, 1999 (64 FR 34608), FDA
published a
[[Page 59779]]
proposed rule to implement section 116 of the Modernization Act by
revising current regulations at 21 CFR 314.70 on supplements and other
changes to an approved application. In that same issue of the Federal
Register (64 FR 34660), FDA published a notice of availability of a
draft guidance for industry entitled ``Changes to an Approved NDA or
ANDA.'' On August 19, 1999, FDA held a public meeting to discuss and
receive comments on the proposed regulations and the draft guidance.
(On August 5, 1999, a notice of the meeting was published in the
Federal Register (64 FR 42625).)
The period for public comment on the proposed regulations closed on
September 13, 1999, and FDA is currently reviewing the comments and
preparing a final rule. The comment period for the draft guidance
closed on August 27, 1999, and FDA has considered these comments when
preparing the guidance that is the subject of this request for
emergency processing.
FDA is requesting emergency processing of this proposed collection
of information under section 3507(j) of the PRA and 5 CFR 1320.13. The
information is needed immediately to implement section 506A of the act,
which provides requirements for making and reporting manufacturing
changes to an approved application and for distributing a drug product
made with such changes. The use of normal information clearance
procedures would likely result in the prevention or disruption of this
collection of information because section 506A takes effect on November
21, 1999. After November 20, 1999, and until final regulations are
issued revising 21 CFR 314.70, section 506A of the act will be the sole
basis for FDA's regulation of postapproval manufacturing changes for
products approved under NDA's or ANDA's. The guidance provides
recommendations to holders of approved NDA's and ANDA's who intend to
make postapproval changes in accordance with section 506A of the act.
Section 506A of the act explicitly provides FDA the authority to use
guidance documents to determine the type of changes that do or do not
have a substantial potential to adversely affect the safety or
effectiveness of the drug product.
Dated: October 29, 1999.
Margaret M. Dotzel,
Acting Associate Commissioner for Policy.
[FR Doc. 99-28793 Filed 11-2-99; 8:45 am]
BILLING CODE 4160-01-F